Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Tilg

Showing results (31-40 of 141) with videos related to

Pageof 15
Sort By:
Digestive Diseases (Basel, Switzerland)|September 14, 2013
Liver complications in inflammatory bowel diseasesV Wieser, R Gerner, A R Moschen, et al.
European Cytokine Network|March 8, 2000
Hepatocyte growth factor plasma levels after myocardial infarction are not affected by recombinant tissue-type plasminogen-activator therapyC Molnar, T Buratti, C J Wiedermann, et al.
Zeitschrift Fur Gastroenterologie|October 28, 2004
[Infliximab in the treatment of Crohn's disease -- a practical approach. Infliximab and chronic Crohn's disease--Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH]H Tilg, P Knoflach, W Petritsch, et al.
Clinical and Experimental Immunology|October 30, 1999
Interferon-alpha (IFN-alpha) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathwayA Kaser, B Enrich, O Ludwiczek, et al.
European Journal of Pediatrics|September 1, 1996
Circulating interleukin-1 receptor antagonist levels in neonatesR Geiger, H Ellemunter, F M Fink, et al.
Gut|April 15, 2008
Gut, inflammation and osteoporosis: basic and clinical conceptsH Tilg, A R Moschen, A Kaser, et al.
Immunology Letters|March 10, 2000
Dendritic cell migration in different micropore filter assaysS Dunzendorfer, A Kaser, C Meierhofer, et al.
Cytokine|October 1, 1995
Induction of circulating interleukin 10 by interleukin 1 and interleukin 2, but not interleukin 6 immunotherapyH Tilg, M B Atkins, C A Dinarello, et al.
Journal of Clinical Pathology|June 1, 1991
Cachexia and tumour necrosis factor-alpha in cytomegalovirus infectionH Tilg, W Vogel, M Herold, et al.
Current Cancer Drug Targets|May 17, 2007
The kinase inhibitor imatinib--an immunosuppressive drug?D Wolf, H Tilg, H Rumpold, et al.
Pageof 15

Showing results (31-40 of 141) with videos related to

Sort By:
Pageof 15
Digestive Diseases (Basel, Switzerland)|September 14, 2013
Liver complications in inflammatory bowel diseasesV Wieser, R Gerner, A R Moschen, et al.
European Cytokine Network|March 8, 2000
Hepatocyte growth factor plasma levels after myocardial infarction are not affected by recombinant tissue-type plasminogen-activator therapyC Molnar, T Buratti, C J Wiedermann, et al.
Zeitschrift Fur Gastroenterologie|October 28, 2004
[Infliximab in the treatment of Crohn's disease -- a practical approach. Infliximab and chronic Crohn's disease--Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH]H Tilg, P Knoflach, W Petritsch, et al.
Clinical and Experimental Immunology|October 30, 1999
Interferon-alpha (IFN-alpha) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathwayA Kaser, B Enrich, O Ludwiczek, et al.
European Journal of Pediatrics|September 1, 1996
Circulating interleukin-1 receptor antagonist levels in neonatesR Geiger, H Ellemunter, F M Fink, et al.
Gut|April 15, 2008
Gut, inflammation and osteoporosis: basic and clinical conceptsH Tilg, A R Moschen, A Kaser, et al.
Immunology Letters|March 10, 2000
Dendritic cell migration in different micropore filter assaysS Dunzendorfer, A Kaser, C Meierhofer, et al.
Cytokine|October 1, 1995
Induction of circulating interleukin 10 by interleukin 1 and interleukin 2, but not interleukin 6 immunotherapyH Tilg, M B Atkins, C A Dinarello, et al.
Journal of Clinical Pathology|June 1, 1991
Cachexia and tumour necrosis factor-alpha in cytomegalovirus infectionH Tilg, W Vogel, M Herold, et al.
Current Cancer Drug Targets|May 17, 2007
The kinase inhibitor imatinib--an immunosuppressive drug?D Wolf, H Tilg, H Rumpold, et al.
Pageof 15